TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)~* 18～60 years old~* Clozapine resistance was defined as used at least two antipsychotics with different chemical structures with appropriate dosages for a sufficient duration, and recently have received stable dose of clozapine 400 mg or more per day for at least 6 months.~* Signed an informed consent~Exclusion Criteria:~* Patients to be diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) for substance abused, development delayed~* Suffering from serious physical disease and can not accept the treatment~* Allergic to sodium valproate, amisulpride, propofol, succinylcholine or atropine~* Participated in any clinical subject within 30 days~* Pregnancy or lactation~* Inability to sign informed consent because of capacity due due to severe mental illness, significant psychomotor agitation or slowness test completion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- sodium valproate with clozapine (Type: EXPERIMENTAL): sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: sodium valproate with Clozapine
- Modified electroconvulsive therapy with clozapine (Type: EXPERIMENTAL): 12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine
- amisulpride (Type: EXPERIMENTAL): amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: amisulpride with Clozapine
- placebo (Type: PLACEBO_COMPARATOR): The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: placebo with Clozapine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients aged ≥ 20 years of age at the day of obtaining the informed consent~* Patients with histologically confirmed diagnosis of the following:~* Peripheral T-cell Lymphoma, not otherwise specified (PTCL-NOS)~* Anaplastic Large Cell Lymphoma (ALCL ALK-positive/negative)~* Angioimmunoblastic T-cell Lymphoma (AITL)~* Have relapsed or refractory to at least one prior systemic chemotherapy for the above disease (currently requiring therapy)~* Have at least 1 evaluable lesion~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Life expectancy of at least 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SP-02L (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Present with a history of ED and signs and symptoms of BPH.~* Are sexually active with an adult female partner, and expect to remain sexually active with the same adult female partner for the duration of the study.~Main Exclusion Criteria:~* Current treatment with nitrates.~* Prostate-specific antigen (PSA) greater than 10.0 nanogram (ng)/mL at 1st screening.~* PSA greater than or equal to 4.0 to less than or equal to 10.0 ng/mL at 1st screening if prostate malignancy has not been ruled out to the satisfaction of a urologist~* Suffering from other urinary disease like cancer, or infection~* Serious cardiovascular disease~* History of significant renal insufficiency

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
- 5 mg Tadalafil (Type: EXPERIMENTAL): Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period
- 0.2 mg Tamsulosin (Type: OTHER): Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men with primary or hypogonadal osteoporosis or postmenopausal women with osteoporosis in the opinion of the investigator. Subjects must be at high risk for fracture in the opinion of the investigator.~2. Willing to be trained and use the pen-injector daily to the satisfaction of study site personnel.~3. Able to read, understand, and respond to self-administered questionnaires.~4. Without language barrier, cooperative, and expected to return for all follow-up procedures.~5. Have provided written informed consent to participate in this study, according to local regulations after being informed of the risks, medications, and procedures to be used in the study.~   Exclusion Criteria:~6. Any disease of sufficient severity to preclude treatment with teriparatide or participation in and completion of the study as defined by the investigator.~7. Having laboratory values, such as elevated serum calcium, precluding teriparatide treatment as defined by the investigator.~8. Subjects who have an increased baseline risk of osteosarcoma, including those with: Paget's disease of the bone or unexplained elevations of alkaline phosphatase, children and young adults with open epiphyses, and subjects who have received external beam or implant radiation therapy involving the skeleton.~9. History of malignant neoplasms in the 5 years prior to study entry, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated, or history of carcinoma in situ of the cervix or uterus.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: P.Vivax Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with subclinical mono- or mixed P. vivax infections (uPCR) can be enrolled.~* Able to participate as decided by the investigators, and willing to comply with the study requirements and follow-up.~* A participant (or parent/guardian of children below age of consent) is willing and able to give written informed consent to participate in the trial.~Exclusion Criteria:~* Currently pregnant or breastfeeding (female of child-bearing age).~* Inability to tolerate oral treatment.~* Previous episode of haemolysis or severe haemoglobinuria following primaquine.~* Known hypersensitivity or allergy to the study drugs.~* Blood transfusion in last 90 days, since this can mask G6PD deficiency.~* An acute malaria episode requiring treatment.~* A febrile condition due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration).~* Anaemia (Haemoglobin (Hb) \< 9 g/dL~* Presence of any condition which in the judgment of the investigator would place the participant at undue risk or interfere with the results of the study (e.g. serious underlying cardiac, renal or hepatic disease; severe malnutrition; HIV/AIDS; or severe febrile condition other than malaria); co-administration of other medication known to cause haemolysis or that could interfere with the assessment of antimalarial regimens.~* Currently taking medication known to interfere significantly with the pharmacokinetics of primaquine and the schizontocidal study drugs

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: ACTIVE_COMPARATOR): Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
- Control arm (Type: PLACEBO_COMPARATOR): Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Switching to Nicotine Containing Electronic Cigarettes Reduce Health Risk Markers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 to 70~* Smoke ≥5 cigarettes per day for at least the past 12 months~* Smoke regular, filtered cigarettes or machine-rolled cigarettes with a filter~* Exhaled CO measurement ≥6 ppm at baseline visit~* No serious quit attempt in prior month~* Willing to completely cease cigarette consumption and switch to an e-cig~* Willing and able to attend regular visits over a 7-week period~* Able to read and write in English~* Able to understand and consent to study procedures~Exclusion Criteria:~* Unstable or significant medical condition such as COPD, kidney disease, or liver disease in the past 12 months~* Severe immune system disorders~* Women who are pregnant, trying to become pregnant, or nursing~* Use of any non-cigarette nicotine delivery product in the past 7 days~* Use of an e-cig for 5 or more days in the past 28 days or any use in the past 7 days~* Uncontrolled mental illness or substance abuse or inpatient treatment for these conditions in the past 6 months~* History of a seizure disorder or had a seizure in the past 12 months~* Currently or have ever taken medications prescribed to prevent seizures (such as Carbamazepine or Phenobarbital). Using seizure medications for off-label use (indications other than treatment for seizures) will not be included as an exclusion, these will be assessed on a case-by-case basis.~* History of difficulty providing or unwilling to provide blood samples (fainting, poor veins, anxiety, seizures)~* Surgery requiring general anesthesia in the past 6 weeks~* Use of marijuana or any illicit drug/prescription drugs for non-medical use daily/almost daily or weekly in the past 3 months per NIDA Quick Screen~* Use of hand-rolled, roll your own cigarettes~* Known allergy to propylene glycol or vegetable glycerin~* Other member of household currently participating in the study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nicotine-Containing Electronic Cigarette (Type: EXPERIMENTAL): The experimental group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 58 mg/ml nicotine for the duration of 6 weeks.
- Non-Nicotine Electronic Cigarette (Type: PLACEBO_COMPARATOR): The placebo group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 0 mg/ml nicotine for the duration of 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 50-99 years~2. Clinical diagnosis of early Alzheimer's disease (Clinical Dementia Rating (CDR) = 0.5, Mini-Mental State Exam (MMSE) = 24-30)~3. If using drugs to treat symptoms related to Alzheimer's disease, doses must be stable for at least eight weeks prior to screening visit 1~4. Labs: Adequate blood cell counts (white blood cells: 4,000-111,000 cells per microliter (cells/mcL); absolute neutrophil count: 1,800-8,700 cells/mcL; platelets: 120-500 K/µL; hemoglobin 12.0-17.5 grams/dL); LFT's within 2x normal value; creatinine clearance test (CrCl) ≥ 50 mL/min; cholesterol (≤260 mg/dl), triglycerides≤ 400 mg/dl), and glucose control (HbA1c ≤ 8%). Prothrombin time/partial thromboplastin time/international normalized ratio (PT/PTT/INR) within normal limits~5. Body mass index (BMI) within range of 19 - 35 kg/m2~6. Must have a reliable informant or caregiver~7. Participants must have no plans to travel that interfere with study visits~Exclusion Criteria:~1. Any medical or neurologic condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment~2. Clinically significant unstable psychiatric illness in the past six months~3. Significant hearing, vision, or motor deficits that interfere with participation~4. Alcohol or drug abuse/dependence in the past six months~5. Stroke, transient ischemic attack, or unexplained loss of consciousness in the past six months~6. Unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within the past six months~7. Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities~8. Diagnosis of HIV infection or AIDS (CD4 count \< 200), HIV/Hepatitis B Virus (HBV) co-infection, HBV or human T-cell leukemia virus infection~9. History of impaired renal or liver function~10. Current use of memantine or sorbitol-containing products~11. Individuals with HIV, HBV, or who have current/previous use of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) or non-NRTIs.~12. Poorly controlled blood pressure (BP) (systolic BP \> 160, diastolic BP \> 90 mmHg)~13. Uncontrolled diabetes (HbA1c \> 8%, or the current use of insulin)~14. Significant systematic illness or infection in the past 30 days~15. Pregnant women

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label 3TC (Type: EXPERIMENTAL): 12 subjects will receive 3TC, 300-mg, daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. between 18 and 74 years of age,~2. have stable coronary artery disease and diabetes mellitus, already on DAPT with aspirin and clopidogrel for at least 6 months,~Exclusion Criteria:~1. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,~2. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,~3. history of clinical and/or hemodynamic instability,~4. within 1 month of placement of a bare metal stent,~5. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,~6. planned coronary revascularization,~7. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h,~8. use of an oral anticoagulation agent or international normalized ratio \>1.5,~9. body weight \<60 kg,~10. age \>75 years,~11. hemoglobin \<10 g/dL,~12. platelet count \<100×106/μL,~13. creatinine \>2 mg/dL,~14. hepatic enzymes \>2.5 times the upper limit of normal,~15. pregnancy and/or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGLT2i (Type: EXPERIMENTAL): Empagliflozin 25 mg per oral once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must be HIV+ men/women starting their first episode of ART or starting a new ART treatment episode and was prescribed medications that suppressed the virus to \<400 copies during their last treatment~* understand that they will be prescribed ART medications that they have never received and to which their virus is likely to be susceptible~* viral loads of 1,000 copies or more~* meet the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria for opioid dependence in early remission~* have a negative opiate urine toxicology and alcohol breath test~* show no evidence of physiologic dependence on physical exam and following a naltrexone challenge~* have a stable address in the St. Petersburg or Leningrad Region of Russia area~* have a valid telephone number where subject can be reached~* have a negative pregnancy test and use adequate contraception~* have the ability to give informed consent as judged by ability to read the consent and correctly answer 9 of 10 questions about the study on a quiz that will be administered after discussing the study and reading the consent~Exclusion Criteria:~* not be currently psychotic as determined by a psychiatric examination (i.e.; schizophrenia, paranoid disorder, mania)~* not have current suicidal or homicidal ideation requiring immediate attention as determined at baseline assessment~* not have an uncontrolled seizure disorder~* not have cognitive impairment with an inability to read and understand the consent~* not have significant laboratory abnormality such as \>2 grade anemia~* not have hepatic transaminase levels \>5 times the upper limit of normal~* not have serum creatinine \>1.5 times the upper limit of normal~* not have pending legal charges with impending incarceration~* not be concurrently participating in another treatment study~* not currently taking naltrexone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Oral Naltrexone + ART (Type: ACTIVE_COMPARATOR): Naltrexone (oral). 50 mg maintenance daily for 48 weeks, plus group drug counseling manual driven, N= 100
- Naltrexone Implant + ART (Type: ACTIVE_COMPARATOR): Naltrexone Implant + ART. Monthly maintenance for 48 Weeks plus, group drug counseling manual driven, N=100

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CLL according to World Health Organization diagnostic criteria~* Active disease~* No previous treatment~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~Exclusion Criteria:~* Transformation to aggressive B-cell malignancy (prolymphocytic leukemia, large-cell lymphoma, Hodgkin's lymphoma)~* Other malignancies except for localized skin cancer~* Continuous systemic corticosteroid treatment~* Known infection with hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab + Fludarabine + Cyclophosphamide (Type: EXPERIMENTAL): Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter \[mg/m\^2\] as intravenous \[IV\] infusion on Day 0 of Cycle 1 and 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m\^2 on Days 1-3) and cyclophosphamide (250 mg/m\^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m\^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* People with Type I or Type II Diabetes~* 18 Years or Older.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete